Navigation Links
Symbiomix Therapeutics Receives FDA Approval of Solosec™ (secnidazole) Oral Granules Following Four-Year Collaboration with Catalent
Date:10/2/2017

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today welcomed Symbiomix Therapeutics’ announcement that the U.S. Food and Drug Administration (FDA) has approved Solosec™ (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. [1] Catalent began working with Symbiomix in 2014 to improve the manufacturing process, and developed a scalable and robust method centered on its expertise in fluid bed coating technology, which is being utilized in manufacturing operations.

Solosec™, a next-generation, 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties, is the first and only single-dose oral therapy for BV, the most common gynecologic infection in the U.S. [1,2] Following FDA approval on September 15, 2017, Solosec™ is expected to be available to patients in early 2018 with at least 10 years of U.S. market exclusivity.

“The FDA’s approval of this new drug marks the culmination of many years of hard work, expertise and dedication by Symbiomix, with support from Catalent’s formulation development team in Somerset,” commented Jonathan Arnold, Catalent's ?vice president and general manager, Drug Delivery Solutions. “We have been able to leverage our skills in fluid bed coating at manufacturing scale to assist in bringing this first-of-its-kind therapy to the market, quickly and effectively.”

BV is the most prevalent gynecologic infection in the U.S., affecting 21 million women ages 14 to 49. According to the Centers for Disease Control and Prevention (CDC), if left untreated, BV increases the risk of transmission of sexually transmitted diseases, including chlamydia, trichomaniasis, gonorrhea, herpes and HIV, and increases the risk of pre-term birth and low birth weight. [2,3]

“Our partnership with Catalent was pivotal in the development of the first and only single-dose oral therapy for BV,” said Robert Jacks, President & CFO of Symbiomix. “Symbiomix is focused on bringing innovative therapies to market for prevalent gynecologic infections that can have serious health consequences, and we are thrilled to provide women with a new, effective treatment option that can be taken any time of day.”

Catalent provided services to Symbiomix at its 260,000-square foot facility in Somerset, which houses state-of-the-art development laboratories, as well as clinical and commercial manufacturing plants for oral dose forms.

Indication
SOLOSEC™ (secnidazole) 2g oral granules is a 5-nitroimidazole antimicrobial agent indicated for the treatment of bacterial vaginosis in adult women.
Important Safety Information

  •     SOLOSEC is contraindicated in patients with a history of hypersensitivity to secnidazole, other ingredients of the formulation, or other nitroimidazole derivatives.
  •     Vulvo-vaginal candidiasis may develop with SOLOSEC and require treatment with an antifungal agent.
  •     Potential risk of carcinogenicity in patients taking single-dose of SOLOSEC to treat bacterial vaginosis is unclear. Chronic use should be avoided.
  •     SOLOSEC may pass into breast milk. Patients should discontinue breastfeeding for 96 hours after administration of SOLOSEC.
  •     SOLOSEC is a single-dose therapy for oral use. The entire contents of SOLOSEC packet should be sprinkled onto applesauce, yogurt or pudding and consumed once within 30 minutes without chewing or crunching the granules. SOLOSEC is not intended to be dissolved in any liquid.
  •     In clinical studies, the most common adverse events occurring in (=2%) of patients receiving SOLOSEC 2g oral granules were vulvovaginal candidiasis (9.6%), headache (3.6%), nausea (3.6%), dysgeusia (3.4%), vomiting (2.5%), diarrhea (2.5%), abdominal pain (2.0%), and vulvovaginal pruritus (2.0%).

To report SUSPECTED ADVERSE REACTIONS, contact Symbiomix Therapeutics at 1-844-SOLOSEC (1-844-765-6732) or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch
Please visit http://www.solosec.com for full Prescribing Information.

About Symbiomix Therapeutics, LLC
Symbiomix (sim-bye-OH-mix) Therapeutics is a biopharmaceutical company focused exclusively on bringing innovative therapies to market for prevalent gynecologic infections that can have serious health consequences. The Company received FDA approval for Solosec™ (secnidazole) 2g oral granules, the first and only single-dose therapy for the treatment of bacterial vaginosis (BV) in adult women.
Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world’s leading healthcare venture capital firms: OrbiMed, F-Prime Capital Partners, and HBM Partners. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut. Please visit https://symbiomix.com/ and follow the Company on LinkedIn and Twitter for more information.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated more than $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

References
1.    Solosec [Package Insert]. Newark, NJ: Symbiomix Therapeutics.
2.    Koumans E.H., Sternberg M, Bruce C, et al. (2007) “The Prevalence of Bacterial Vaginosis in the United States, 2001-2004: Associations with Symptoms, Sexual Behaviors, and Reproductive Health.” Sex Transm Dis. 34(11): 864-869.
3.    https://www.cdc.gov/std/bv/stdfact-bacterial-vaginosis.htm.

Read the full story at http://www.prweb.com/releases/2017/10/prweb14757958.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Thermo Fisher Scientific Enables Targeted Therapeutics by Utilizing Transcriptomics
2. NEW Ingredient: Euromed SA Partners with Biotherapeutics Inc. to Launch the First Abscisic Acid Nutritional Ingredient to Market
3. Innovations Series Explores Advances in Therapeutics for Treatment and Diagnosis of Disease
4. Open Therapeutics and AuthorAID to Cooperate on Advancing Scientific Knowledge
5. Blue Door Therapeutics Paving the Way to Treat the Opioid Epidemic with $2 Million Dollar Treatment Center in North Scottsdale
6. Coalition Duchenne Congratulates Capricor Therapeutics on Positive Six-Month Results from its Randomized CAP-1002 Phase I/II HOPE Clinical Trial in Duchenne
7. MAP and Lief Therapeutics Partner to Track Anxiety Real-time in Substance Use Disorder Populations
8. Just Biotherapeutics, Inc., Hangzhou Just Biotherapeutics, Ltd., and G-CON Manufacturing, Inc. Announce Collaboration on State of the Art Bioprocess Facility in China
9. Prof. Nishimura to Present Emerging Technologies for Evaluation of Biotherapeutics at Pittcon 2017 JAIMA Symposium
10. The Challenges and Opportunities for Cannabis-Based Therapeutics: Catalent to Present at Upcoming Industry Conference
11. T3D Therapeutics Receives FDA Approval for a 6-Month, Open-Label Extension to its Phase 2a Trial of T3D-959 for Treatment of Mild to Moderate Alzheimer’s Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2019)... , ... June 25, 2019 , ... Women’s Excellence welcomes ... in Louisiana and has been a practicing midwife for over 3 years. Prior ... received her Master’s in Nursing from Frontier University and her undergraduate from Northwestern University. ...
(Date:6/24/2019)... ... 2019 , ... Cibo Vita, Inc., makers of Nature’s Garden, NutriPops, Chocolate Orchard ... indulgence snack line at the 65th annual Summer Fancy Food Show, taking place at ... booth #5721. , The company’s expansive product portfolio features a variety of trail ...
(Date:6/20/2019)... (PRWEB) , ... June 20, 2019 , ... ... a portfolio company of Chicago Pacific Founders, announced a strategic partnership with Northern ... The partnership expands SightMD’s leading position in New York, adding the Company’s first ...
(Date:6/19/2019)... ... June 19, 2019 , ... CEO Steven C. Bilt of ... CEOs in 2019 . Glassdoor , one of the world’s largest job ... leaders employees love working for in countries throughout North America and parts of Europe. ...
(Date:6/19/2019)... ... June 19, 2019 , ... LifeLearn Animal Health launches PetInsuranceInfo.com, a new pet ... it isn’t, and the questions they need to ask prior to purchasing a policy. ... companies and find the coverage that meets their budget and pet’s health care needs. ...
Breaking Medicine News(10 mins):
(Date:6/24/2019)... ANGELES (PRWEB) , ... June 24, 2019 , ... ... 43% of labs worldwide currently use a laboratory information management system, or LIMS. ... next two years. This is according to a new report, " The 2019 ...
(Date:6/24/2019)... ... June 24, 2019 , ... Enespro PPE , a ... for the electrical industry has today announced the release of its guide for ... titled Developing a Culture of Electrical Safety, is written to address the continued ...
(Date:6/20/2019)... (PRWEB) , ... June 20, 2019 , ... Phlexglobal today ... Trial Master Files. The guidance took effect on June 6, 2019, and promises to ... well as related departments and systems. , At 17 pages and going into specific ...
Breaking Medicine Technology: